Blog: Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies

Pioneering joint venture releases 58 of 200 planned, highly-specific recombinant antibodies

New Collaborative Agreement - Life Technologies has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research. Read More

Date Posted: 07/20/12